TY - JOUR
T1 - Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
AU - Ho, Ping Chih
AU - Bihuniak, Jessica Dauz
AU - MacIntyre, Andrew N.
AU - Staron, Matthew
AU - Liu, Xiaojing
AU - Amezquita, Robert
AU - Tsui, Yao Chen
AU - Cui, Guoliang
AU - Micevic, Goran
AU - Perales, Jose C.
AU - Kleinstein, Steven H.
AU - Abel, E. Dale
AU - Insogna, Karl L.
AU - Feske, Stefan
AU - Locasale, Jason W.
AU - Bosenberg, Marcus W.
AU - Rathmell, Jeffrey C.
AU - Kaech, Susan M.
N1 - Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/9/10
Y1 - 2015/9/10
N2 - Activated T cells engage aerobic glycolysis and anabolic metabolism for growth, proliferation, and effector functions. We propose that a glucose-poor tumor microenvironment limits aerobic glycolysis in tumor-infiltrating T cells, which suppresses tumoricidal effector functions. We discovered a new role for the glycolytic metabolite phosphoenolpyruvate (PEP) in sustaining T cell receptor-mediated Ca2+-NFAT signaling and effector functions by repressing sarco/ER Ca2+-ATPase (SERCA) activity. Tumor-specific CD4 and CD8 T cells could be metabolically reprogrammed by increasing PEP production through overexpression of phosphoenolpyruvate carboxykinase 1 (PCK1), which bolstered effector functions. Moreover, PCK1-overexpressing T cells restricted tumor growth and prolonged the survival of melanoma-bearing mice. This study uncovers new metabolic checkpoints for T cell activity and demonstrates that metabolic reprogramming of tumor-reactive T cells can enhance anti-tumor T cell responses, illuminating new forms of immunotherapy.
AB - Activated T cells engage aerobic glycolysis and anabolic metabolism for growth, proliferation, and effector functions. We propose that a glucose-poor tumor microenvironment limits aerobic glycolysis in tumor-infiltrating T cells, which suppresses tumoricidal effector functions. We discovered a new role for the glycolytic metabolite phosphoenolpyruvate (PEP) in sustaining T cell receptor-mediated Ca2+-NFAT signaling and effector functions by repressing sarco/ER Ca2+-ATPase (SERCA) activity. Tumor-specific CD4 and CD8 T cells could be metabolically reprogrammed by increasing PEP production through overexpression of phosphoenolpyruvate carboxykinase 1 (PCK1), which bolstered effector functions. Moreover, PCK1-overexpressing T cells restricted tumor growth and prolonged the survival of melanoma-bearing mice. This study uncovers new metabolic checkpoints for T cell activity and demonstrates that metabolic reprogramming of tumor-reactive T cells can enhance anti-tumor T cell responses, illuminating new forms of immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=84941366350&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941366350&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2015.08.012
DO - 10.1016/j.cell.2015.08.012
M3 - Article
C2 - 26321681
AN - SCOPUS:84941366350
SN - 0092-8674
VL - 162
SP - 1217
EP - 1228
JO - Cell
JF - Cell
IS - 6
ER -